Overall rank by patents
#15,910
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
CV6 Therapeutics (ni) Limited
USPTO PatentsView assignee record - 18 granted patents across 6 technology areas, active 2020–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
18
Total patents granted
6
CPC technology areas
13.7
Avg claims per patent
-
5-year filing velocity
The verdict
CV6 holds 18 US patents across 6 technology areas, rank #15,910 of 50,000 tracked assignees.
- #15,910
- of 50,000 US assignees by volume
- Top 69%
- by Innovation Score (29.6/100)
- 13.7
- avg claims per patent
Portfolio overview
CV6 Therapeutics (NI) Limited has been granted 18 US utility patents between 2020 and 2024, placing CV6 Therapeutics (NI) Limited at rank #15,910 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.7 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a Foreign Corporation, CV6 Therapeutics (NI) Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 29.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2024, with 18 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. CV6 Therapeutics (NI) Limited's 13.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark CV6 Therapeutics (NI) Limited against peers pursuing similar technology classes.
How does CV6 compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- CV6 Therapeutics… ◀ 18
CV6 Therapeutics (NI) Limited
18 patents
What this shows CV6 holds 18 patents, placing it at rank #15,910 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
CV6's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 69% higher than 31% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2020–2024
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 7 | 38.9% |
| 2021 | 6 | 33.3% |
| 2022 | 3 | 16.7% |
| 2023 | 1 | 5.6% |
| 2024 | 1 | 5.6% |
Which technologies does CV6 Therapeutics (NI) Limited patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Frequently Asked Questions
How many patents does CV6 Therapeutics (NI) Limited hold?
CV6 Therapeutics (NI) Limited holds 18 US granted patents filed between 2020 and 2024, spanning 6 technology areas.
What is CV6 Therapeutics (NI) Limited's Innovation Score?
CV6 Therapeutics (NI) Limited has an Innovation Score of 29.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does CV6 Therapeutics (NI) Limited focus on?
CV6 Therapeutics (NI) Limited's top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 18 patents. The company has filed patents in 6 CPC subclasses total.
Is CV6 Therapeutics (NI) Limited's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for CV6 Therapeutics (NI) Limited.
What does claim depth mean for CV6 Therapeutics (NI) Limited's patents?
CV6 Therapeutics (NI) Limited's patents average 13.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the CV6 Therapeutics (NI) Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
CV6's 18 grants land it in the top 69% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - CV6 ranks #15,910 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07D - see who else leads that technology area. C07D leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
C07D technology
CV6 Therapeutics (NI) Limited's primary CPC class, all holders and yearly trends
Top 50 patent holders
See where CV6 Therapeutics (NI) Limited ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
